TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.

导出原文传递

翻译打印收藏纠错

第一作者： Kaifeng,Jin

第一单位： Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, PR China.;NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China.

作者： Kaifeng,Jin ^[1] ; Jingtong,Xu ^[2] ; Xiaohe,Su ^[3] ; Ziyue,Xu ^[3] ; Bingyu,Li ^[2] ; Ge,Liu ^[3] ; Hailong,Liu ^[4] ; Yiwei,Wang ^[5] ; Yu,Zhu ^[6] ; Le,Xu ^[7] ; Weijuan,Zhang ^[2] ; Zhaopei,Liu ^[8] ; Zewei,Wang ^[9] ; Yuan,Chang ^[6] ; Jiejie,Xu ^[3]

作者单位： Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, PR China.;NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China. ^[1] Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China. ^[2] NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China. ^[3] Department of Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China. ^[4] Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China. ^[5] Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, PR China. ^[6] Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China. ^[7] NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China.;Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, PR China. ^[8] Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, PR China. ^[9]

关键词 PD‐1/PD‐L1 blockade TP53 mutations chemoimmunotherapy platinum‐based chemotherapy urothelial carcinoma